Gold Prices Surge as U.S.-Iran Ceasefire Talks Spark Market Optimism 
U.S. Stock Futures Steady Amid Iran Ceasefire Talks and Trump Address 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Asian Stocks Drop as Trump Signals Iran War Escalation 
Vietnam GDP Growth Slows in Q1 2026 Amid Middle East Oil Crisis 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple Turns 50: From Garage Startup to AI Crossroads 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Oil Prices Surge Over $5 as Trump Vows to Continue Iran Strikes 
U.S. Job Market Braces for Slow Recovery Amid Middle East Tensions and Economic Uncertainty 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
South Korea's Inflation Rises Modestly in March Amid Oil Price Pressures 
Australia's Trade Surplus Surges in February on Gold Export Boom 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Morgan Stanley: Fed Rate Cuts Still on Track Despite Oil-Driven Inflation 
Medtronic plc, a leading global healthcare technology company headquartered in Dublin, Ireland, is set to acquire EOFlow, a wearable insulin patch maker based in South Korea, for $738 million.
The Korea Economic Daily reported that Medtronic confirmed it has signed a share purchase agreement (SPA) to buy all the shares of EOFlow's chief executive officer Jesse Kim and president Luis Malave. The medical device company said that their shares are priced at KRW30,000 per share or about $22.60.
The price is said to be higher 19.8% higher compared to the KRW25,050 closing stock price on Friday, May 26. This is also said to be EOFlow's highest share price since November 2021, and the surge was hinted to be due to Medtronic's acquisition plan of the company.
EOFlow said that its CEO Jesse Kim currently owns the biggest stake in the company, and he signed a SPA with Medtronic Korea Holdings for the sale of the 18.58% stake, which he owns for KRW169.2 billion. On the other hand, EOFlow's president Luis Malave holds less than five percent of the company.
"Our goal is to simplify diabetes management and deliver the well-established benefits of automated insulin delivery to our customers in the ways they want and need," Medtronic Diabetes' executive vice president and president, Que Dallara, said in a press release. "We are excited to introduce a differentiated wearable patch option to provide more patient choice and drive further innovation for those who want to use technology to make living with diabetes easier."
EOFlow's founder and CEO, Jesse Kim, added, "We are thrilled to accelerate our next phase of growth with a partner like Medtronic who shares our goal of simplifying diabetes management to make life easier for the customers we serve."
Meanwhile, JP Morgan Securities LLC has been assigned by Medtronic as its financial advisor for the transaction, while Kim & Chang and Ropes & Gray LLP serve as its legal advisors. For EOFlow, it has hired Goldman Sachs & Co. LLC as its financial advisor and Bae, Kim & Lee LLC acting as its legal advisor.
Photo by Tony Webster/Flickr(CC BY 2.0)
